Second-Player Prunella Vulgaris Oral Liquid Approved, Breaking Guiyang Xintian's Monopoly
Start here
On September 2, 2026, Jiangxi Heying Pharmaceutical's Prunella vulgaris oral liquid received an NMPA registration certificate (Guoyao Zhunzi Z20263002) and was approved for marketing. The single-herbal-ingredient oral liquid, classified as a prescription drug under medical insurance category B, is described as the third same-name same-formula traditional Chinese medicine nationally and in practice the first approved without a technical linkage. Its approval ends Guiyang Xintian Pharmaceutical's long-standing monopoly on the product, opening the market to a second player. What market share Jiangxi Heying can capture, and whether further approvals of same-name same-formula traditional Chinese medicines follow, is still open.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comJiangxi Heying's Prunella Vulgaris Oral Liquid Wins NMPA Registration, Ending Guiyang Xintian's Long Monopoly
Jiangxi Heying Pharmaceutical's Prunella vulgaris oral liquid received an NMPA registration certificate (Guoyao Zhunzi Z20263002) on September 2, 2026, and was approved for marketing. The article calls it the third same-name same-formula traditional Chinese medicine nationally and in practice the first approved without a technical linkage, and says its approval ends Guiyang Xintian Pharmaceutical's long-standing monopoly. The drug is an oral liquid made from a single herbal ingredient, classified as a prescription drug under medical insurance category B.
Heat trend for this story
Heat now 7·Peak in the comparable set 10 (Oct 24 19:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.